158 related articles for article (PubMed ID: 31721173)
1. A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
Wang R; Shao X; Zheng J; Saci A; Qian X; Pak I; Roy A; Bello A; Rizzo JI; Hosein F; Moss RA; Wind-Rotolo M; Feng Y
Clin Pharmacol Ther; 2020 Apr; 107(4):978-987. PubMed ID: 31721173
[TBL] [Abstract][Full Text] [Related]
2. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R; Zheng J; Shao X; Ishii Y; Roy A; Bello A; Lee R; Zhang J; Wind-Rotolo M; Feng Y
J Immunother Cancer; 2019 Dec; 7(1):348. PubMed ID: 31829287
[TBL] [Abstract][Full Text] [Related]
3. Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
Bajaj G; Gupta M; Feng Y; Statkevich P; Roy A
J Clin Pharmacol; 2017 Dec; 57(12):1527-1533. PubMed ID: 28800166
[No Abstract] [Full Text] [Related]
4. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
[No Abstract] [Full Text] [Related]
5. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
[No Abstract] [Full Text] [Related]
6. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
[No Abstract] [Full Text] [Related]
8. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
9. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
10. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Weber JS; Sznol M; Sullivan RJ; Blackmon S; Boland G; Kluger HM; Halaban R; Bacchiocchi A; Ascierto PA; Capone M; Oliveira C; Meyer K; Grigorieva J; Asmellash SG; Roder J; Roder H
Cancer Immunol Res; 2018 Jan; 6(1):79-86. PubMed ID: 29208646
[TBL] [Abstract][Full Text] [Related]
11. Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma.
Umemura H; Kaji T; Tachibana K; Morizane S; Yamasaki O
Int J Biol Markers; 2019 Dec; 34(4):414-420. PubMed ID: 31648585
[TBL] [Abstract][Full Text] [Related]
12. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M
J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.
Hamuro L; Statkevich P; Bello A; Roy A; Bajaj G
Clin Pharmacol Ther; 2019 Nov; 106(5):1018-1027. PubMed ID: 31090921
[TBL] [Abstract][Full Text] [Related]
14. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
[No Abstract] [Full Text] [Related]
15. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
16. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Bochem J; Zelba H; Amaral T; Spreuer J; Soffel D; Eigentler T; Wagner NB; Uslu U; Terheyden P; Meier F; Garbe C; Pawelec G; Weide B; Wistuba-Hamprecht K
PLoS One; 2019; 14(8):e0221301. PubMed ID: 31419253
[TBL] [Abstract][Full Text] [Related]
17. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
